AUG 7, 2026 · PHASE 2 TRIAL
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
ClinicalTrials.gov
Phase 2 interventional trial in an active but unrecruitment stage with no results reported in this registry record; design and endpoints are specified but outcome data are absent.
Reported
Planned enrollment77
PhasePHASE2
Primary endpoint (Primary Analysi…Overall Response Rate (ORR): Percentage of…